证券日报网讯亿帆医药10月30日在互动平台回答投资者提问时表示，公司与美国合作方的销售提成收 入，其权利义务在第三季度已经形成。公司在获取第三季度销售数据后，将其确认为第三季度的收入。 （文章来源：证券日报） ...

Core Viewpoint - Company’s wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has participated in the 11th national centralized drug procurement organized by the National Joint Procurement Office, with some products expected to be selected for this procurement [1][2]. Group 1: Product Information - The products proposed for selection include Ephedrine Hydrochloride Injection and Meprobamate Injection, which received drug registration certificates from the National Medical Products Administration in March 2023 and August 2024, respectively [2]. - The final prices and supply provinces for the selected products will be based on the data released by the Joint Procurement Office [1]. Group 2: Impact on the Company - The sales revenue from the proposed selected products currently accounts for a small proportion of the company's total revenue, and it is expected that there will be no significant impact on the company's performance in the short term [2]. - If the company successfully signs procurement contracts and implements them, it will enhance the accessibility of the products and improve the company's brand influence [2].

Group 1 - Core viewpoint: Yifan Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected, including adrenaline hydrochloride injection [1] - Revenue composition for the first half of 2025: Pharmaceuticals accounted for 85.53%, pharmaceutical raw materials and intermediates 11.47%, and high molecular materials 3.0% [1] - Current market capitalization of Yifan Pharmaceutical is 16 billion yuan [1]

Core Viewpoint - Yifan Pharmaceutical (002019) announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected for this procurement [1] Group 1 - Yifan Pharmaceutical's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., is involved in the bidding process for the centralized procurement [1] - The products involved in the bidding include Adrenaline Hydrochloride Injection and Meprobamate Injection, which are intended to be selected in this round of procurement [1]

关于全资子公司参与全国药品集中采购拟中选的公告 证券代码：002019 证券简称：亿帆医药 公告编号：2025-061 亿帆医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025年10月27日，亿帆医药股份有限公司（以下简称"公司"）全资子公司 合肥亿帆生物制药有限公司参加了国家组织药品联合采购办公室（以下简称"联 合采购办公室"）组织的第十一批全国药品集中采购的投标工作。公司部分产品 拟中选本次集中采购。现将相关情况公告如下： | 药品名称 | 适应症 | 剂型 | 规格 包装 | 拟中选价格 （元/支） | 拟主供省 | | | 采购周期 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 盐酸去氧肾 | 用于治疗休克及麻醉时维 | | 1ml:10mg | | 福建、四川、 | 自 中 | 选 | | 结 | 果 | 执 | | | 上腺素注射 | 持血压。也用于控制阵发性 | 注射剂 | 5支/盒 | ...

Core Points - Yifan Pharmaceutical (002019) responded to investor inquiries on October 24, detailing the milestone payments for Yilishu in the U.S. market, which include upfront payments, milestone payments upon product launch, and sales milestone payments [1] - The revenue from Yilishu encompasses shipping revenue and sales sharing payments [1]

证券日报网讯亿帆医药（002019）10月24日在互动平台回答投资者提问时表示，截至2025年10月20日公 司股东人数为47，150户。 ...

Core Viewpoint - Yifan Pharmaceutical stated on October 24 that it will fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations if there are any significant matters [2] Company Summary - Yifan Pharmaceutical responded to investor inquiries on an interactive platform regarding its commitment to timely information disclosure [2]

Core Viewpoint - Yifan Pharmaceutical stated that its production and operations are currently normal, and it adheres strictly to legal regulations and disclosure requirements, with no undisclosed significant matters or premature performance leaks [1] Group 1 - The company confirmed that it is operating normally and in compliance with relevant laws and regulations [1] - There are no significant matters that should have been disclosed but were not [1] - The company denied any incidents of performance information being leaked in advance [1]

Core Viewpoint - Yifan Pharmaceutical (002019) emphasizes its commitment to sustainable development, focusing on environmental protection, social responsibility, and corporate governance [1] Group 1 - The company has consistently prioritized sustainable development [1] - The company values environmental protection as part of its operational strategy [1] - The company is dedicated to fulfilling its social responsibilities [1]